PAREXEL APPOINTS LEADING CENTRAL NERVOUS SYSTEM EXPERTS TO ITS GLOBAL CLINICAL PHARMACOLOGY BUSINESS
BOSTON, MA, April 2, 2008 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that Larry Ereshefsky, Pharm.D., F.C.C.P., B.C.C.P., and Malek Bajbouj, M.D., have been appointed as Vice Presidents of Clinical Pharmacology Consulting Services in the Company’s international clinical pharmacology business. These leading experts advise clients on early phase clinical development in the central nervous system (CNS) therapeutic area, including in regard to psychiatry, neuropsychopharmacology, and neurophysiology clinical studies. Dr. Ereshefsky is based at PAREXEL’s Clinical Pharmacology Research Unit in Los Angeles, California in the United States and Dr. Bajbouj is based at the unit in Berlin, Germany.
“Clients increasingly rely on our experts to help identify and select the most promising compounds in the Phase I and Proof of Concept stages. These decisions are based on demonstrating safety and signals of efficacy as early as possible in the drug development process,” said Herman Scholtz, M.D., Corporate Vice President and Worldwide Head, Clinical Pharmacology, PAREXEL. “We expect that the extensive medical and scientific expertise Dr. Ereshefsky and Dr. Bajbouj bring to our clinical pharmacology business will further strengthen our central nervous system capabilities in order to help biopharmaceutical companies address growing complexity in this important area of early phase clinical development.”
Dr. Larry Ereshefsky is Board Certified in Psychiatric Pharmacy, and has more than 28 years of experience in the neuropsychopharmacology and psychiatry fields. His expertise includes all phases of clinical research and psychopharmacological evaluations of medications for the treatment of a broad range of CNS and psychiatry disorders. Dr. Ereshefsky is a leader in CNS clinical study design and research methodologies, and has served on U.S. Food and Drug Administration (FDA) and United States Pharmacopeia (USP) advisory boards. Prior to joining PAREXEL, Dr. Ereshefsky was Chief Scientific Officer at California Clinical Trials. He was formerly Professor of Psychiatry and Pharmacology at The University of Texas Health Science Center in San Antonio, Texas in the United States. Previously, he was Associate Director of Research at San Antonio State Hospital, and held principal investigator and clinical consulting positions at several medical institutions. Dr. Ereshefsky received a Pharm.D. degree from the University of Southern California (USC), and completed his residency at the Los Angeles County-USC Medical Center. He currently serves on the Executive Committee of The International Society for CNS Clinical Trials and Methodology, and has served as Presidential Officer of the College of Psychiatric and Neurological Pharmacists. He is a frequent presenter, has authored more than 100 articles, and has held editorial advisory positions for major psychiatry, pharmacologic, and psychiatric pharmacy publications.
Dr. Malek Bajbouj is Board Certified in Psychiatry and Clinical Neurophysiology. He has expertise in CNS biomarkers and the development of new physiological procedures, including neurophysiological and neuroimaging measures used in cognitive function research. His research background also includes genetics, antidepressive stimulation techniques, and sleep medicine. Dr. Bajbouj is a Professor at the Charité University in Berlin, Germany, where he heads the Electroencephalography Lab and Neuromodulation Unit. He also serves as Co-Director of the Affective Disorder Module and the Sleep Laboratory at the university. Dr. Bajbouj is a permanent member of the university’s Drug Commission and Doctoral Commission. He holds several professional memberships, including the Society of Biological Psychiatry. Dr. Bajbouj serves on the editorial boards of several scientific journals including The American Journal of Psychiatry, Experimental Neurology, and The Open Neuroscience Journal. He has been published extensively in the fields of neurophysiology, neuroimaging, neuromodulation, sleep medicine, and genetics.
In addition to the units noted above, PAREXEL’s other Clinical Pharmacology Research Units are located in San Diego, California in the United States; London, United Kingdom; and Bloemfontein and George, South Africa. PAREXEL also provides early clinical development programs through a joint venture arrangement with Synchron Research based in India.
For more information about PAREXEL’s international clinical pharmacology capabilities, visit: http://www.parexel.com/early_phase.html.